Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Rabbit risk score can help rheumatologists identify patients at high risk of infection

08.06.2012
New study validates score as new tool

Results of a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, suggest that the newly developed RABBIT Risk Score, which calculates the risk of serious infections in patients with rheumatoid arthritis (RA) who are treated with anti-tumour necrosis factor drugs (anti-TNFs) or conventional disease modifying anti-rheumatic drugs (DMARDs) is a valid and effective tool for rheumatologists to predict risk of serious infection.

The German study used data from 2,603 patients enrolled in the RABBIT register at the start of treatment with anti-TNFs (n=1,327) or conventional DMARDs (n=1,276). The likelihood of serious infection based on individual risk profiles was calculated using the RABBIT risk score. The score was developed by the same group of researchers on a different patient sample.

There was good agreement between observed and expected rates of serious infections. In the anti-TNF group, expected number of infections was 31.5 versus actual number observed which was 33. For conventional DMARDs, the expected number of infections was 14.8 versus the actual number observed which was 13.

"The results of our study validate the RABBIT Risk Score as a useful tool to help identify RA patients at high risk of developing infections when treated with anti-TNFs or DMARDs," said Professor Angela Zink from the German Rheumatism Research Centre in Berlin, Germany. "This tool could help rheumatologists identify at-risk patients and avoid treatment combinations that have a higher risk of infectious complications. This could also help reducing costs associated with treating the infections."

In patients who had ¡Ý1 risk factor, including chronic lung disease, chronic renal disease, and age above 60 years, the RABBIT Risk Score also successfully predicted infection (10.0 expected vs 9.0 observed in DMARD group, 6.4 expected vs 6 observed in anti-TNF group).

Abstract Number: OP0144

* Strangfeld et al, Ann Rheum Dis. 2011;70(11):1914-20

NOTES TO EDITORS:
For further information on this study, or to request an interview with the study lead, please do not hesitate to contact the EULAR congress Press Office in Hall 6 on the 3rd floor of the Congress Centre during EULAR 2012 or on:

Email: eularpressoffice@cohnwolfe.com

Candice Debleu:
Onsite tel: +44 7894 386 425
About EULAR
The European League Against Rheumatism (EULAR) is the organisation which represents the patient, health professional and scientific societies of rheumatology of all the European nations

In line with The European Union of Medical Specialists (UEMS), EULAR defines rheumatology as including rheumatic diseases of the connective tissue, locomotor and musculoskeletal systems

EULAR aims to promote, stimulate and support the research, prevention, treatment and rehabilitation of rheumatic diseases. With 45 scientific member societies, 36 PARE organisations and 10 health professionals associations, EULAR underscores the importance of combating rheumatic diseases not only by medical means, but also through a wider context of care for rheumatic patients and a thorough understanding of their social and other needs

Diseases of the bone and joints such as rheumatoid arthritis and osteoarthritis cause disability in 4-5% of the adult population and are predicted to rise as people live longer

EULAR 2012 is set to be the biggest rheumatology event in Europe with over 15,000 scientists, physicians, allied health professionals, and related audiences in attendance from over 115 countries. Over the course of the congress, more than 275 oral and 1400 poster abstract presentations will be featured, with 1,010 invited speaker lectures taking place in 190 sessions

To find out more about the activities of EULAR, visit: www.eular.org

Candice Debleu | EurekAlert!
Further information:
http://www.eular.org

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>